Page 1 | Search Results | Blood | American Society of Hematology

1-8 of 8

Sort by

Sort Order Select

Journal Articles

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Yaël C. Cohen, Philippe Moreau, Jaszianne Tolbert, Xiang Qin, Xuewen Ma, Diego Vieyra, Angelique Langlois, Christelle Courtoux, William Terry, Lixia Pei, Christoph Heuck, Peter Voorhees

Blood (2022) 140 (Supplement 1): 4418–4419.

https://doi.org/10.1182/blood-2022-162733

Published: 2022

Journal Articles

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Manisha Bhutani, MD, Monika House, RN, BA, Jiaxian He, MS, Shebli Atrash, David M Foureau, PhD, Barry Paul, MDMS, Reed Friend, MD, James T Symanowski, PhD, Sarah Norek, BSN, RN, Xhevahire Begic, MSPH, Donna Acampora, BSN, RN, Katherine K Farmer, BA, Carrie Ann Syfert, BSN, RN, Mauricio Pineda-Roman, MD, Peter Voorhees, MD, Saad Z. Usmani, MDMBBS,MBA

Blood (2020) 136 (Supplement 1): 38–39.

https://doi.org/10.1182/blood-2020-138485

Published: 2020

Journal Articles

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

Ajay Nooka, MDMPH, Hans C. Lee, MD, Ashraf Z. Badros, MD, Peter Voorhees, MD, Malin Hultcrantz, MD PhD, Lionel Karlin, MD, Bertrand Arnulf, MD, Paul G. Richardson, MD, Eric Zhi, PhD, January Baron, MS, Trisha Piontek, BSN, Eric Lewis, MD, Joanna Opalinska, MD PhD, Ira Gupta, MD, Adam D. Cohen, MD, Sagar Lonial, MD FACP

Blood (2020) 136 (Supplement 1): 22–23.

https://doi.org/10.1182/blood-2020-139687

Published: 2020

Journal Articles

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

Blood (2018) 132 (20): 2115–2124.

https://doi.org/10.1182/blood-2018-07-862334

Published: 2018

Includes: Supplemental data

Journal Articles

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

Blood (2017) 129 (12): 1646–1657.

https://doi.org/10.1182/blood-2016-10-746933

Published: 2017

Journal Articles

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

Frits Van Rhee, MD, PhD, Luis Fayad, MD, Peter Voorhees, MD, Richard R Furman, MD, Hossein Borghaei, DO, MS, Sagar Lonial, MD, Lubomir Sokol, MD, PhD, Julie Crawford, BS, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Jennifer Herring, RN, Xiang Qin, MS, Razelle Kurzrock, MD

Blood (2008) 112 (11): 1008.

https://doi.org/10.1182/blood.V112.11.1008.1008

Published: 2008

Journal Articles

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Razelle Kurzrock, MD, Luis Fayad, Peter Voorhees, MD, Richard R Furman, MD, Sagar Lonial, MD, Hossein Borghaei, DO, MS, Sundar Jagannath, MD, Lubomir Sokol, MD, PhD, Mark Cornfeld, MD, MPH, Ming Qi, MD, PhD, Trina Jiao, MS, Jennifer Herring, RN, Xiang Qin, PhD, Frits van Rhee, MD, PhD

Blood (2008) 112 (11): 1009.

https://doi.org/10.1182/blood.V112.11.1009.1009

Published: 2008

Journal Articles

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

Jean-Francois Rossi, MD, PhD, Robert F. Manges, MD, Heather J. Sutherland, MD, PhD, Sundar Jagannath, MD, Peter Voorhees, MD, Pieter Sonneveld, MD, Michel Delforge, MD, PhD, Brigitte Pegourie, MD, Adrian Alegre, MD, Javier de la Rubia, MD, David La Police, BS, Rajesh Bandekar, PhD, Hong Xie, MD, Robert Z. Orlowski, MD, PhD

Blood (2008) 112 (11): 867.

https://doi.org/10.1182/blood.V112.11.867.867

Published: 2008

NARROW

MonumenTAL-3: Phase 3 Trial of Talquetamab + Daratumumab ± Pomalidomide Versus Daratumumab + Pomalidomide + Dexamethasone in Relapsed/Refractory Multiple Myeloma Following ≥1 Prior Line of Therapy

Response-Adaptive Phase II Study of Daratumumab Combined with Carfilzomib, Lenalidomide and Dexamethasone in Newly Diagnosed Multiple Myeloma

Infusion-Related Reactions (IRRs) in the DREAMM-2 Study of Single-Agent Belantamab Mafodotin (Belamaf) in Patients with Relapsed/Refractory Multiple Myeloma (RRMM)

International, evidence-based consensus treatment guidelines for idiopathic multicentric Castleman disease

International, evidence-based consensus diagnostic criteria for HHV-8–negative/idiopathic multicentric Castleman disease

CNTO 328, a Monoclonal Antibody to Interleukin-6, Is Active as a Single Agent in Castleman’s Disease: Preliminary Results of a Phase I Study.

A Phase I Study of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody in Patients with B-Cell Non-Hodgkin’s Lymphoma, Multiple Myeloma, or Castleman’s Disease.

Preliminary Results of CNTO 328, An Anti-Interleukin-6 Monoclonal Antibody, in Combination with Bortezomib in the Treatment of Relapsed or Refractory Multiple Myeloma

Email alerts

ASH Publications

American Society of Hematology

Email alerts

ASH Publications

American Society of Hematology

This Feature Is Available To Subscribers Only